J 2021

Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS

PAVELEK, Zbysek, Lukas SOBISEK, Jana SARLAKOVA, Pavel POTUZNIK, Marek PETERKA et. al.

Basic information

Original name

Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS

Authors

PAVELEK, Zbysek (203 Czech Republic, guarantor), Lukas SOBISEK (203 Czech Republic), Jana SARLAKOVA (203 Czech Republic), Pavel POTUZNIK (203 Czech Republic), Marek PETERKA (203 Czech Republic), Ivana STETKAROVA (203 Czech Republic), Pavel ŠTOURAČ (203 Czech Republic, belonging to the institution), Jan MARES (203 Czech Republic), Pavel HRADILEK (203 Czech Republic), Radek AMPAPA (203 Czech Republic), Marketa GRUNERMELOVA (203 Czech Republic), Marta VACHOVA (203 Czech Republic), Eva RECMANOVA (203 Czech Republic), Francesco ANGELUCCI, Simona HALUSKOVA (203 Czech Republic) and Martin VALIS (203 Czech Republic)

Edition

FRONTIERS IN NEUROLOGY, LAUSANNE, FRONTIERS MEDIA SA, 2021, 1664-2295

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30210 Clinical neurology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 4.086

RIV identification code

RIV/00216224:14110/21:00121730

Organization unit

Faculty of Medicine

DOI

UT WoS

000611503800001

Keywords in English

multiple sclerosis; treatment; long-term therapy; clinical practice; DMD

Tags

Tags

International impact, Reviewed
Změněno: 8/6/2021 12:44, Mgr. Tereza Miškechová

Abstract

V originále

Background: Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system. Well-established drugs used for MS patients after the first demyelinating event in the Czech Republic include glatiramer acetate (GA), interferon beta-1a (IFN beta-1a), IFN beta-1b (IFN beta-1b), peginterferon beta-1a (peg-IFN beta-1a), and teriflunomide. Objective: The objective of this observational study was to compare the effectiveness of the abovementioned drugs in patients with MS who initiated their therapy after the first demyelinating event. Patients were followed for up to 2 years in real clinical practice in the Czech Republic. Methods: A total of 1,654 MS patients treated after the first demyelinating event and followed up for 2 years were enrolled. Evaluation parameters (endpoints) included the annualized relapse rate (ARR), time to next relapse, change in the Expanded Disability Status Scale (EDSS) score, and time of confirmed disease progression (CDP). When patients ended the therapy before the observational period, the reason for ending the therapy among different treatments was compared. Results: No significant difference was found among the groups of patients treated with IFN beta-1a/1b, GA, or teriflunomide for the following parameters: time to the first relapse, change in the EDSS score, and the proportion of patients with CDP. Compared to IFN beta-1a (44 mcg), a significant increase in the percentage of relapse-free patients was found for GA, but this treatment effect was not confirmed by the validation analysis. Compared to the other drugs, there was a significant difference in the reasons for terminating GA therapy. Conclusion: Small differences were found among GA, IFN beta and teriflunomide therapies, with no significant impact on the final outcome after 2 years. Therefore, in clinical practice, we recommend choosing the drug based on individual potential risk from long-term therapy and on patient preferences and clinical characteristics.